Trends in Cancer

Article	Citations
Dying to survive: harnessing inflammatory cell death for better immunotherapy	268
Advisory Board and Contents	201
Subscription & copyright page	161
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	153
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	147
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments	137
Subscription & copyright page	130
On the path to equity in cancer research and care	127
Subscription & copyright page	124
Challenges and opportunities for physician-scientists in advancing cancer research	117
Subscription and copyright page	114
Subscription & copyright page	109
Ancestry-defined molecular taxonomy of prostate cancer	107
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	103
Subscription & copyright page	102
Advisory Board and Contents	98
Subscription &copyright page	97
Quantifying Cancer: More Than Just a Numbers Game	97
State-matched organoid models to fight pancreatic cancer	94
Subscription & copyright page	94
Subscription & copyright page	93
Integrating Quantitative Approaches in Cancer Research and Oncology	93
Advisory Board and Contents	91
Interferon signaling restrains renal cell carcinoma heterogeneity	87
Advisory Board and Contents	85

Revumenib: a new era in acute leukemia treatment	82
Pearls and pitfalls of ChatGPT in medical oncology	80
Advisory Board and Contents	80
Advisory Board and Contents	77
Space in cancer biology: its role and implications	74
Matrix stiffness primes cells for future oxidative stress	73
FBXW10: a male-biased E3 ligase in liver cancer	72
Ferroptosis vulnerability in FLT3-mutant leukemia	71
‘Slicing’ glioblastoma drivers with the Swiss cheese model	64
Endogenous retroelements as alarms for disruptions to cellular homeostasis	62
Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance	61
Engineered bacterial therapeutics for detecting and treating CRC	60
Label-free optical imaging for brain cancer assessment	59
Targeting TEAD-ious resistance	58
Engineering growth factor ligands and receptors for therapeutic innovation	58
Concepts and Applications of Information Theory to Immuno-Oncology	57
Solving the puzzle of what makes immunotherapies work	57
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies	54
Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?	54
Targeting the Mevalonate Pathway in Cancer	53
Into the era of mycobiome-driven cancer research	53
Impact of tissue-agnostic approvals on management of primary brain tumors	53
A Quantitative Paradigm for Decision-Making in Precision Oncology	52
Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression	51
Serrated colorectal cancer: preclinical models and molecular pathways	50
Protease regulation of tumor-immune cell symbiosis	50
Tumor mutational burden and immunotherapy in gliomas	49
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	49
Adverse effects of ferroptotic therapy: mechanisms and management	49
Innate lymphoid cells: potential targets for cancer therapeutics	48
Evolution of metastasis: new tools and insights	47
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	47
Myeloid cell path to malignancy: insights into liver cancer	47
Cancer cell adaptability: turning ribonucleoprotein granules into targets	46
Clonal evolution and hierarchy in myeloid malignancies	46
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	46
Targeting synthetic lethal paralogs in cancer	45
Tumor-resident microbes: the new kids on the microenvironment block	44
Advances in targeting RNA modifications for anticancer therapy	44
Advances in LAG3 cancer immunotherapeutics	43
Integrating innate and adaptive immunity in oncolytic virus therapy	43
The peritumor microenvironment: physics and immunity	41
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents	40
Epigenetic basis and targeting of cancer metastasis	40
Tumor-agnostic drug development in dMMR/MSI-H solid tumors	40
How Comorbidities Shape Cancer Biology and Survival	38
Necroptosis and tumor progression	38
Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors	38
Metastatic hormone-naïve prostate cancer: a distinct biological entity	38
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA	37

IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	37
Next batter up! Targeting cancers with KRAS-G12D mutations	37
Advisory Board and Contents	36
Addressing the genetic/nongenetic duality in cancer with systems biology	36
Subscription and copyright page	36
Subscription and copyright page	35
Subscription & copyright page	34
Advisory Board and Contents	34
Next-generation cancer vaccines and emerging immunotherapy combinations	34
Apart, together	34
Subscription & copyright page	34
Subscription & copyright page	33
Subscription and copyright page	33
Advisory Board and Contents	33
Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies	32
Emerging metabolomic tools to study cancer metastasis	32
Advisory Board and Contents	31
CD4+ T cells help myeloid-mediated killing of immune-evasive tumors	31
Advisory Board and Contents	31
The development of therapy related myeloid neoplasms in childhood cancer survivors	31
Chemical-genetics refines transcription factor regulatory circuits	31
Subscription & copyright page	30
Advisory Board and Contents	30
Prognostic value of atypical B cells in breast cancer	30
Subscription & copyright page	30
Subscription & copyright page	30
NETscape or NEThance: tailoring anti-cancer therapy	29
Epigenetic control of immunoevasion in cancer stem cells	29
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	29
Leveraging circulating microbial DNA for early cancer detection	28
Radiotherapy-induced metabolic hallmarks in the tumor microenvironment	28
Aberrant nuclei with amplified DNA in cancer	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
Subscription & copyright page	27
Next-generation immunotherapies for brain metastatic cancers	27
Biophysical determinants of cancer organotropism	27
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	27
Subscription & copyright page	26
High-Fat Diet Impacts on Tumor Development in the Gut	26
Exercise against nonsmall-cell lung carcinoma: novel insights	26
COX2-dependent suppression of anticancer immunity	26
Advisory Board and Contents	25
Immunomodulation by endothelial cells: prospects for cancer therapy	24
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	24
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer	24
Turning cold into hot: emerging strategies to fire up the tumor microenvironment	23
Engine shutdown: migrastatic strategies and prevention of metastases	22
Emerging roles of TBK1 in cancer immunobiology	22
Advisory Board and Contents	22
Metabolic landscape of disseminated cancer dormancy	22
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	21
Emerging roles of nucleotide metabolism in cancer	21
Immunogenicity of ferroptosis in cancer: a matter of context?	21
Accessing the vasculature in cancer: revising an old hallmark	20
Antibody–drug conjugates: in search of partners of choice	20
Metabolic interplay: tumor macrophages and regulatory T cells	20
Cellular and molecular mechanisms of plasticity in cancer	19
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	19
Perivascular niches: critical hubs in cancer evolution	19
Drug independence and the curability of cancer by combination chemotherapy	19
Multifunctional role of thymidine phosphorylase in cancer	19
Radiotherapy and immunotherapy: open questions and future strategies	19
Role of financial toxicity in perpetuating health disparities	19
Convergent insights into intratumor heterogeneity	18
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms	18
Onco-condensates: formation, multi-component organization, and biological functions	18
Redrawing therapeutic boundaries: microbiota and cancer	18
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities	18
Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms	18
Immune organoids: from tumor modeling to precision oncology	18
Genitourinary cancer neoadjuvant therapies: current and future approaches	18
The conundrum of Helicobacter pylori-associated apoptosis in gastric cancer	18
Better together: circulating tumor cell clustering in metastatic cancer	17
Gut Microbiota in Cancer Immune Response and Immunotherapy	17
CAR T cell therapies for diffuse midline glioma	17
Neuro-immune interactions and immuno-oncology	17
The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer	17
Understanding the role of sex hormones in cancer for the transgender community	17
Navigating life as an early career researcher	17

Immunometabolism of CD8+ T cell differentiation in cancer	17
Insights into LINE-1 reverse transcription guide therapy development	16
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	16
Lifileucel: the first cellular therapy approved for solid tumours	16
T follicular helper cells in cancer	16
Variant allele frequency: a decision-making tool in precision oncology?	16
Intestinal stem cell dynamics in homeostasis and cancer	15
Advisory Board and Contents	15
Regulation of metastatic organotropism	15
Shadow mentoring: a cost–benefit review for reform	15
The unequal burden of time toxicity	15
Advisory Board and Contents	14
Deciphering the roles of ABCB5 in normal and cancer cells	14
Immune cells in residual disease and recurrence	14
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	14
Plant-derived cannabinoids as anticancer agents	14
Benefits and opportunities of the transgenic Oncopig cancer model	14
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC	14
Cys-regulation: oxidized CHK1 controls cross-compartment circuit of chemoresistance	14
Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi	14
Oncology-respirology: a discipline in dire need	14
Crosstalk of T cells within the ovarian cancer microenvironment	13
Persisting cancer cells are different from bacterial persisters	13
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	13
Trends in cancer imaging	13
myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy	13
Targeting immunogenic cell death for glioma immunotherapy	13
Chromatin as an old and new anticancer target	13
GSDME: A Potential Ally in Cancer Detection and Treatment	13
Successfully targeting the cancer system with metronomics for medulloblastoma	13
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	13
Targeting cancer stem cells in multiple myeloma	13
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	13
Illuminating Non-genetic Cellular Heterogeneity with Imaging-Based Spatial Proteomics	12
An epigenetic signature in CD19-CAR T cells predicts clinical outcome	12
Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities	12
CHEK2 variants: linking functional impact to cancer risk	12
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	12
Advisory Board and Contents	12
Subscription & copyright page	12
Optimizing the future: how mathematical models inform treatment schedules for cancer	12
Subscription and copyright page	12
Advisory Board and Contents	12
CFTR and colorectal cancer susceptibility: an urgent need for further studies	11
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	11
Transcriptomic subtyping of gastrointestinal malignancies	11
Natural killer cells: unlocking new treatments for bladder cancer	11
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights	11
Subscription & copyright page	11
Environmental pollutants and bad bugs work hand in glove	11
Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment	11
Elevated circulating memory T cells precede immunotherapy toxicities in melanoma	11
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	10
T cell-mediated additive cytotoxicity – death by multiple bullets	10
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	10
Cancer fitness genes: emerging therapeutic targets for metastasis	10
Pannexin biology and emerging linkages to cancer	10
GOT2 consider the tumor microenvironment	10
Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors	10
The origin of novel traits in cancer	10
T cell exhaustion in malignant gliomas	9
Methionine restriction and antitumor immunity	9
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research	9
Generation of tumor neoantigens by RNA splicing perturbation	9
Tilting MYC toward cancer cell death	9
Subscription & copyright page	9
Selective autophagy receptor hinders antitumor immunity	9
A big step for MYC-targeted therapies	9
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	9
Tumor immunology CRISPR screening: present, past, and future	9
Gut microbiota – a double-edged sword in cancer immunotherapy	9
Cancer researchers as storytellers for the lay public	9
C1q+ macrophages: passengers or drivers of cancer progression	8
Technical and biological constraints on ctDNA-based genotyping	8
Sweet dreams: glycosylation controls tumor cell dormancy	8
Recent developments in myeloid immune modulation in cancer therapy	8
A hormetic response model for glutamine stress in cancer	8
Compromised epigenetic robustness in cancer: fueling evolution, exposing weakness	8
The enigma of maladaptation in gastric pathophysiology	8
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	8
Future perspectives on engineered T cells for cancer	8
Challenges in glioblastoma research: focus on the tumor microenvironment	8
Oncogenic competence: balancing mutations, cellular state, and microenvironment	8
Immunotherapy for colorectal cancer: insight from inherited genetics	8
The future of cancer research: invest now	8
Weaponizing natural killer cells for solid cancer immunotherapy	8
The spectrum of sex differences in cancer	8
Neuronal and tumourigenic boundaries of glioblastoma plasticity	8
Subscription & copyright page	8
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	8
Lymph node metastasis fuels systemic disease	8
Low tumor mutational burden and immunotherapy in gliomas	8
Coagulome and the tumor microenvironment: an actionable interplay	7
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	7
Embracing diversity: macrophage complexity in cancer	7